CJC-1295 with DAC Research Overview (also known as CJC-1295 DAC, DAC:GRF)
A long-acting synthetic analog of Growth Hormone Releasing Hormone (GHRH) modified with a Drug Affinity Complex (DAC) that covalently binds albumin in the bloodstream, extending the half-life to 6–8 days. Produces sustained, non-pulsatile GH secretion over days from a single injection. Studied for body composition, recovery, and anti-aging protocols requiring infrequent dosing.
What Is CJC-1295 with DAC?
CJC-1295 with DAC is a 30-amino-acid synthetic peptide analog of GHRH carrying a Drug Affinity Complex — a lysine-based linker that covalently binds to circulating serum albumin after injection. This albumin binding shields the peptide from enzymatic degradation and extends its half-life from the ~30-minute window of native GHRH to approximately 6–8 days.
Mechanism of Action
CJC-1295 DAC binds to and activates GHRH receptors on somatotroph cells in the anterior pituitary, triggering growth hormone synthesis and secretion. Because the DAC-modified peptide circulates for days rather than minutes, it produces a sustained elevation in GH levels rather than a sharp pulse — a pharmacokinetic profile fundamentally distinct from native GHRH and from the no-DAC version.
Research Applications
Studies have investigated CJC-1295 DAC for GH replacement, body composition optimization (lean mass gain, fat reduction), recovery from injury and training, and anti-aging protocols. Its once-weekly or twice-weekly dosing schedule makes it a practical subject for sustained GH secretagogue research compared to daily injections.
Comparison with No-DAC Version
The key distinction between CJC-1295 with DAC and without DAC (Modified GRF 1-29) is the pharmacokinetic profile. DAC produces steady, blunted GH elevation over days. No-DAC produces sharp, physiologically normal GH pulses that closely mimic the body's natural secretion pattern. Researchers select between them based on whether sustained baseline elevation or pulsatile mimicry is the research objective.
Quick Reference
| Literature-Reported Dose Range | 1-2mg (0.5-1mL if mixed at 2mg/mL) |
| Literature-Reported Frequency | Once weekly - same day each week |
| Literature-Reported Cycle Length | 8-12 weeks maximum |
| Literature-Reported Washout | 4-6 weeks mandatory to prevent desensitization |
| Storage | Refrigerate immediately, more stable than non-DAC - use within 60 days |
| Sites Reported in Studies | Subcutaneous: Abdomen (preferred), outer thigh, deltoid area |
| Timing | Any time of day - timing less critical due to long half-life |
Research Indications
Growth Hormone
Sustained GH Elevation
Provides continuous growth hormone release for 6-8 days per injection
IGF-1 Optimization
Significantly elevates IGF-1 levels for extended periods
Convenience Protocol
Weekly dosing schedule ideal for those seeking simple administration
Body Composition
Fat Loss Enhancement
Continuous GH elevation promotes lipolysis and fat metabolism
Lean Mass Gains
Sustained anabolic environment supports muscle protein synthesis
Body Recomposition
Simultaneous fat loss and muscle gain potential
Anti-Aging
Skin Rejuvenation
Extended GH/IGF-1 elevation may improve skin elasticity and thickness
Energy Levels
Users report improved vitality and reduced fatigue
Recovery Enhancement
Accelerated healing and recovery from exercise or injury
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Conservative Anti-Aging | 1mg | Once weekly | SubQ |
| Standard Protocol | 2mg | Once weekly | SubQ |
| Split Dosing | 1mg | Twice weekly (Mon/Thu) | SubQ |
| Loading Protocol | 2mg first week, then 1mg | Weekly | SubQ |
Timing
Recommended administration window: any time of day - timing less critical due to long half-life. Typical onset: iGF-1 elevation within 24-48 hours, peak benefits weeks 2-6, body composition changes weeks 4-8.
Peptide Interactions
Can be combined but continuous GH elevation from DAC version may reduce synergistic benefits of pulsatile protocols
GHRP pulse effects are diminished when combined with continuous GH elevation from CJC-1295 DAC
Never combine different CJC-1295 variants - choose based on desired release pattern
Both provide continuous GH elevation - combination may lead to excessive and unnatural GH levels
Both are GHRH analogs competing at the same receptor. Combining provides no benefit and may cause receptor desensitization. Choose one GHRH analog per protocol.
Combining with exogenous HGH defeats the purpose and may suppress natural production
Both are GHRH analogs that bind the same GHRH receptor. Combining them creates receptor competition and provides no meaningful additive benefit over using a single, appropriately dosed GHRH analog. Choose one GHRH analog per protocol.
Reported Research Timeline
01Week 1 (reported in cited studies): possible water retention, improved sleep, increased appetite
02Week 2–3 (reported in cited studies): noticeable recovery improvements, some report joint discomfort
03Week 4–6 (reported in cited studies): visible body composition changes, increased vascularity
04Week 6–8 (reported in cited studies): continued improvements but watch for desensitization signs
05Post-cycle: Maintain most gains, IGF-1 returns to baseline in 2-3 weeks
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Higher side effect incidence than pulsatile protocols
Common: Water retention, joint pain, carpal tunnel symptoms
Monitor for signs of excessive GH: jaw growth, hand/feet enlargement
Not suitable for those with diabetes or cancer history
May worsen sleep apnea in predisposed individuals
Regular IGF-1 monitoring recommended for long-term use
Seek Medical Attention If:
Severe joint pain or carpal tunnel syndrome
Excessive water retention affecting daily life
Numbness or tingling in extremities
Significant blood glucose dysregulation
Any signs of acromegaly (enlarged features)
Persistent lethargy indicating adrenal effects
Quality Indicators
Verified Marker
High purity requirement
DAC peptides require >98% purity - impurities cause more side effects
Verified Marker
Proper DAC labeling
Legitimate products clearly state "with DAC" to distinguish from regular CJC-1295
Acceptable Range
More expensive than non-DAC
DAC version costs 2-3x more due to complex manufacturing
Acceptable Range
Foaming during mixing
Normal for DAC peptides to foam - wait for foam to settle
Quality Concern
Extremely cheap pricing
If priced similar to non-DAC version, likely mislabeled or fake
Quality Concern
Clear solution immediately
Should be slightly cloudy initially - immediate clarity may indicate non-DAC
Research Citations
Research Focus
Growth hormone release, Body composition, Recovery, Anti-aging, Muscle preservation
Verified Vendors Carrying CJC-1295 with DAC
Frequently Asked Questions
What should researchers watch for with CJC-1295 with DAC?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with CJC-1295 with DAC?
Week 1 (reported in cited studies): possible water retention, improved sleep, increased appetite
How is CJC-1295 with DAC typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →